To the bone

До косточки

Журнал: Non nocere. Новый терапевтический журнал. 2025;(12): 28‑35

Прочитано: 79 раз

Связаться с автором

Оглавление

Как цитировать:

До косточки. Non nocere. Новый терапевтический журнал. 2025;(12):28‑35.
To the bone. Non Nocere. New Therapeutic Journal. 2025;(12):28‑35. (In Russ.)

Использование инфографики авторами научных работ

Литература / References:

Рубрикатор клинических рекомендаций. Клинические рекомендации. Ревматоидный артрит [Электронный ресурс]. Год утверждения: 2024. ID: 250_3. Возрастная категория: взрослые. Дата обращения: 16.10.2025. https://cr.minzdrav.gov.ru/view-cr/250_3
Zhang Z, Gao X, Liu S, et al. Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20-54 years from 1990 to 2021. Sci Rep. 2025 Mar 28;15(1):10736. https://doi.org/10.1038/s41598-025-92150-1
Okada Y, Eyre S, Suzuki A, Kochi Y, Yamamoto K. Genetics of rheumatoid arthritis: 2018 status. Ann Rheum Dis. 2019 Apr;78(4):446-453. https://doi.org/10.1136/annrheumdis-2018-213678
Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun Rev. 2020 Jun;19(6):102528. https://doi.org/10.1016/j.autrev.2020.102528
Firestein GS. Pathogenesis of rheumatoid arthritis: the intersection of genetics and epigenetics. Trans Am Clin Climatol Assoc. 2018;129:171-182.
Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm (2020). 2024 Mar 10;5(3):e509. https://doi.org/10.1002/mco2.509
Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):3-18. https://doi.org/10.1016/j.berh.2017.08.003
Peterson E, Gallagher MK, Wilbur J. Rheumatoid Arthritis: Diagnosis and Management for the Family Physician. Am Fam Physician. 2024 Nov;110(5):515-526.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-2581. https://doi.org/10.1002/art.27584
Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep;62(9):2582-2591. https://doi.org/10.1002/art.27580
Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. https://doi.org/10.1136/ard-2022-223356
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. https://doi.org/10.1002/acr.24596
Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2023 Jan;75(1):15-22. https://doi.org/10.1002/art.42347
Felson D, Lacaille D, LaValley MP, Aletaha D. Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment. Ann Rheum Dis. 2022 Jan;81(1):4-7. https://doi.org/10.1136/annrheumdis-2021-221653